Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Prognostic Factors in Limited-Stage Small Cell Lung Cancer
Farris, Michael K., Mix, M. , Wang, Xiaofei , Jaszewski, Brandy L., Foster, Nathan R. , Laurie, Fran, Smith, Koren, Alden, Ryan S. , Komaki, Ritsuko , Stinchcombe, Thomas E. , Bradley, Jeffrey D. , Bogart, Jeffrey A. , Jaszewski, Brandy, Bradley, Jeffrey , Farris, Michael K , Masters, Gregory A. , Razavian, Niema B , Vokes, Everett E.

Mayo Clinic

JAMA Network Open | October 24, 2024 | Volume: 7 | Issue: 10 | Pages: e2440673

10.1001/jamanetworkopen.2024.40673 | PMID 39446327 Get It

Importance The impact of patient-specific, disease-related, and social factors on outcomes in limited-stage small cell lung cancer (LS-SCLC) is not well defined. A post hoc secondary analysis of such factors from the Cancer and Leukemia Group B (CALGB) 30610–Radiation Therapy Oncology Group (RTOG) 0538 trial may impact future trial design. Objective To assess the comprehensive demographic, disease-related, treatment-related, and social factors for potential associations with survival outcomes and understand whether specific subpopulations may benefit from radiotherapy (RT) dose escalation in LS-SCLC. Design, Setting, and Participants This post hoc secondary analysis of a randomized clinical trial included 638 adults with LS-SCLC treated at 186 unique treatment sites with at least 1 accrual for all patients from March 15, 2008, to December 1, 2019; 313 patients were randomized to receive RT twice daily to a dosage of 45 Gy for 3 weeks and 325 to receive RT once daily to a dosage of 70 Gy for 7 weeks. Data were locked February 28, 2022, and analyzed from November 28, 2022, to June 4, 2024. Interventions Twice-daily RT or once-daily RT. Main Outcomes and Measures Multivariable Cox proportional hazards models evaluated the association of treatment groups and other risk factors with progression-free survival (PFS) and overall survival (OS). Patient-specific factors included age, sex, and Eastern Cooperative Oncology Group performance status. Disease-related factors included tumor, nodal, and overall cancer stages. Treatment-related factors included type of chemotherapy, timing of concurrent RT, RT technique, and prophylactic cranial irradiation. Social factors included marital status and treatment center accrual volume. Results Among 507 patients (260 [51.3%] female and 247 [48.7%] male; mean [SD] age, 62.6 [7.9] years) included in the multivariate survival analysis, with a median follow-up of 4.7 (IQR, 3.7-7.1) years, female sex was associated with improved OS (hazard ratio [HR], 0.73 [95% CI, 0.58-0.91]; P = .006), while being 70 years or older was associated with decreased OS (HR, 1.50 [95% CI, 1.14-1.98]; P = .004). Neither age nor sex was associated with PFS. When compared with those with N1 disease, OS and PFS were worse in patients with N2 (HRs, 1.64 [95% CI, 1.19-2.26]; P = .002 and 1.36 [95% CI, 1.02-1.81]; P = .04, respectively) and N3 (HRs, 2.03 [95% CI, 1.40-2.93]; P < .001 and 1.63 [95% CI, 1.17-2.26]; P = .004) disease. Compared with stage II cancer, OS was worse for stage IIIA (HR, 1.65 [95% CI, 1.17-2.31]; P = .004) and stage IIIB (HR, 1.94 [95% CI, 1.34-2.83]; P < .001). Compared with high-volume accrual centers, treatment at low- or middle-volume accrual centers was associated with worse PFS (HRs, 1.94 [95% CI, 1.33-2.82; P < .001] and 1.44 [95% CI, 1.15-1.82; P = .002], respectively) and worse OS (HRs, 1.55 [95% CI, 1.03-2.32; P = .03] and 1.33 [95% CI, 1.04-1.70; P = .02], respectively). Conclusions and Relevance This secondary analysis of the CALGB 30610–RTOG 0538 randomized clinical trial of patients with LS-SCLC found associations between female sex or being younger than 70 years and improved overall survival and between advanced nodal stage or treatment at low- or middle-volume accrual centers and worse outcomes. These findings suggest that stratification by nodal stage, clinical stage, and age should be considered in future randomized trials. Trial Registration ClinicalTrials.gov Identifier: NCT00632853
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Long, Jessica B., Sprenkle, Preston C. , Kim, Isaac Yi , Saperstein, Lawrence, Rabil, Maximilian , Ghaffar, Umar , Karnes, R. Jeffrey , Ma, Xiaomei, Gross, Cary P. , Kunst, Natalia , Westvold, Sarah J. , Wang, Shi‐Yi , Leapman, Michael

Mayo Clinic

JAMA Network Open | October 23, 2024 | Volume: 7 | Issue: 10 | Pages: e2440591

10.1001/jamanetworkopen.2024.40591 | PMID 39441595 Get It

ImportanceAlthough prostate-specific membrane antigen positron emission tomography (PSMA-PET) has shown improved sensitivity and specificity compared with conventional imaging for the detection of biochemical recurrent (BCR) prostate cancer, the long-term outcomes of a widespread shift in imaging are unknown.ObjectiveTo estimate long-term outcomes of integrating PSMA-PET into the staging pathway for recurrent prostate cancer.Design, Setting, and ParticipantsThis decision analytic modeling study simulated outcomes for patients with BCR following initial definitive local therapy. Inputs used were from the literature and a retrospective cohort study conducted at 2 institutions. The base case analysis assumed modest benefits of earlier detection and treatment, and scenario analyses considered prostate-specific antigen (PSA) level at imaging and different outcomes of earlier vs delayed treatment. The analysis was performed between April 1, 2023, and May 1, 2024.Exposures(1) Immediate PSMA-PET imaging, (2) conventional imaging (computed tomography and bone scan [CTBS]) followed by PSMA-PET if CTBS findings were negative or equivocal, and (3) CTBS alone.Main Outcomes and MeasuresThe main outcomes were detection of metastases, deaths from prostate cancer, and life-years and quality-adjusted life-years (QALYs) gained.ResultsThe model estimated that per 1000 simulated patients with BCR (assumed median age, 66 years), PSMA-PET is expected to diagnose 611 (95% uncertainty interval [UI], 565-656) patients with metastasis compared with 630 (95% UI, 586-675) patients diagnosed using CTBS followed by PSMA-PET and 297 (95% UI, 202-410) patients diagnosed using CTBS alone. Moreover, the estimated number of prostate cancer deaths was 512 (95% UI, 472-552 deaths) with PSMA-PET, 520 (95% UI, 480-559 deaths) with CTBS followed by PSMA-PET, and 587 (95% UI, 538-632 deaths) with CTBS alone. Imaging with PSMA-PET yielded the highest number of QALYs, which were 824 (95% UI, 698-885) higher than CTBS. These results differed by PSA level at the time of testing, with the highest incremental life-years and QALYs and lowest number of deaths from prostate cancer among patients with PSA levels of at least 5.0 ng/mL. Finally, the estimates were sensitive to the expected benefit of initiating therapy for recurrent prostate cancer earlier in the disease course.Conclusions and RelevanceThe results of this decision-analytic model suggest that upfront PSMA-PET imaging for the evaluation of BCR is expected to be associated with reduced cancer mortality and gains in life-years and QALYs compared with the conventional imaging strategy, assuming modest benefits of earlier detection and treatment.
Comparative brain metabolomics reveals shared and distinct metabolic alterations in Alzheimer's disease and progressive supranuclear palsy
Batra, Richa , Krumsiek, Jan , Wang, Xue , Allen, Mariet , Blach, Colette , Kastenmüller, Gabi, Arnold, Matthias , Ertekin‐Taner, Nilüfer , Arnold, Matthias , Kastenmüller, Gabi , Kaddurah‐Daouk, Rima

Mayo Clinic

Alzheimer's & Dementia | October 23, 2024 | Volume: 20 | Issue: 12 | Pages: 8294-8307

10.1002/alz.14249 | PMID 39439201 Get It

Abstract BACKGROUND Metabolic dysregulation is a hallmark of neurodegenerative diseases, including Alzheimer's disease (AD) and progressive supranuclear palsy (PSP). Although metabolic dysregulation is a common link between these two tauopathies, a comprehensive brain metabolic comparison of the diseases has not yet been performed. METHODS We analyzed 342 postmortem brain samples from the Mayo Clinic Brain Bank and examined 658 metabolites in the cerebellar cortex and the temporal cortex between the two tauopathies. RESULTS Our findings indicate that both diseases display oxidative stress associated with lipid metabolism, mitochondrial dysfunction linked to lysine metabolism, and an indication of tau‐induced polyamine stress response. However, specific to AD, we detected glutathione‐related neuroinflammation, deregulations of enzymes tied to purines, and cognitive deficits associated with vitamin B. DISCUSSION Our findings underscore vast alterations in the brain's metabolome, illuminating shared neurodegenerative pathways and disease‐specific traits in AD and PSP. Highlights First high‐throughput metabolic comparison of Alzheimer's diesease (AD) versus progressive supranuclear palsy (PSP) in brain tissue. Cerebellar cortex (CER) shows substantial AD‐related metabolic changes, despite limited proteinopathy. AD impacts both CER and temporal cortex (TCX); PSP's changes are primarily in CER. AD and PSP share metabolic alterations despite major pathological differences.
Mitochondrial oxidative phosphorylation capacity in skeletal muscle measured by ultrafast Z ‐spectroscopy ( UFZ ) MRI
Ju, Licheng , Wang, Kexin , Li, Anna , Wu, Yihan , Samuel, T. Jake , Ganji, Sandeep , Yadav, Nirbhay N. , Weiss, Robert G. , Xu, Jiadi , Wang, Kexin , Xu, Jiadi , Ganji, Sandeep K , Schär, Michael , Zijl, Peter C.M. van

Mayo Clinic

Magnetic Resonance in Medicine | October 21, 2024 | Volume: 93 | Issue: 3 | Pages: 1273-1284

10.1002/mrm.30354 | PMID 39428676 Get It

Abstract Purpose To investigate the feasibility of rapid CEST MRI acquisition for evaluating oxidative phosphorylation (OXPHOS) in human skeletal muscle at 3T, utilizing ultrafast Z‐spectroscopy (UFZ) combined with MRI and the Polynomial and Lorentzian line‐shape Fitting (PLOF) technique. Methods UFZ MRI on muscle was evaluated with turbo spin echo (TSE) and 3D EPI readouts. Five healthy subjects performed in‐magnet plantar flexion exercise (PFE) and subsequent changes of amide, PCr, and partial PCr mixed Cr (Cr + ) CEST dynamic signals post‐exercise were enabled by PLOF fitting. PCr/Cr CEST signal was further refined through pH correction by using the ratios between PCr/Cr and amide signals, named PCAR/CAR, respectively. Results UFZ MRI with TSE readout significantly reduces acquisition time, achieving a temporal resolution of <50 s for collecting high‐resolution Z‐spectra. Following PFE, the recovery/decay times (τ) for both PCr and Cr in the gastrocnemius muscle of the calf were notably longer when determined using PCr/Cr CEST compared to those after pH correction with amideCEST, namely = 87.1 ± 15.8 s and = 98.1 ± 20.4 s versus = 32.9 ± 19.7 s and = 43.0 ± 13.0 s, respectively. obtained via 31 P MRS ( = 50.3 ± 6.2 s) closely resemble those obtained from pH‐corrected PCr/Cr CEST signals. Conclusion The outcomes suggest potential of UFZ MRI as a robust tool for non‐invasive assessment of mitochondrial function in skeletal muscles. pH correction is critical for the reliable OXPHOS measurement by CEST.
3D Coaxial Printing of Small‐Diameter Artificial Arteries
Zhu, Yuxiang , Liu, Siying , Mei, Xuan , Lin, Zeng, Pulido, Tiffany V., Hou, Jixin , Remani, Srikar Anudeep, Patil, Dhanush , Ramanathan, Arunachalam , Chambers, Lindsay B. , Yu, Churan , Guo, Shenghan , Zhao, Yiping , Song, Kenan , Song, Kenan , Zhu, Yuxiang , Ramanathan, Arunachalam , Mei, Xuan , Zhao, Yiping , Lin, Zeng, Sobczak, M. Taylor , Thummalapalli, Sri Vaishnavi , Liu, Yang , Wang, Xianqiao , Lancaster, Jessica N. , Zhang, Yu Shrike , Chen, Xiangfan

Mayo Clinic

Small Structures | October 20, 2024 | Volume: 6 | Issue: 2 | Pages: No page available

10.1002/sstr.202400323 Get It

As a treatment for the widely spread cardiovascular diseases (CVD), bypass vascular grafts have room for improvement in terms of mechanical property match with native arteries. A 3D‐printed nozzle is presented, featuring unique internal structures, to extrude artificial vascular grafts with a flower‐mimicking geometry. The multilayer‐structured graft wall allows the inner and outer layers to interfere sequentially during lateral expansion, replicating the nonlinear elasticity of native vessels. Both experiment and simulation results verify the necessity and benefit of the flower‐mimicking structure in obtaining the self‐toughening behavior. The gelation study of natural polymers and the utilization of sacrificial phase enables the smooth extrusion of the multiphase conduit, where computer‐assisted image analysis is employed to quantify manufacturing fidelity. The cell viability tests demonstrate the cytocompatibility of the gelatin methacryloyl (GelMA)/sodium alginate grafts, suggesting potential for further clinical research with further developments. This study presents a feasible approach for fabricating bypass vascular grafts and inspires future treatments for CVD.
Carfilzomib Prescribing Patterns and Outcomes for Relapsed or Refractory Multiple Myeloma: A Real-World Analysis
Dong, Sharlene , Banerjee, Rahul , Khan, Adeel , Wang, Xiaoliang , Afghahi, Anosheh , Afrough, Aimaz , Janakiram, Murali , Cowan, Andrew J. , Banerjee, Rahul , Wang, Xiaoliang , Janakiram, Murali , Wang, Mengru , Wang, Bo , Sperling, Adam S. , Anderson, Larry D. , Rajkumar, S. Vincent , Kaur, Gurbakhash

Mayo Clinic

No container title available | October 17, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4839164/v1 Get It

Abstract Despite the widespread use of carfilzomib (K) in relapsed/refractory multiple myeloma (RRMM), there is no consensus on optimal K dose in milligrams per square meter (mg/m2) or dosing schedule. We assessed three modern K prescribing patterns in RRMM using a large United States electronic health record-derived database. Our final cohort (n = 486) included 136 patients (28.0%) who received K 56 mg/m2 once weekly (K56-1x), 86 (17.7%) who received 56 mg/m2 twice weekly (K56-2x), and 264 (54.3%) who received 70 mg/m2 once weekly (K70-1x). Between 2016 and 2023, once-weekly dosing became more common: K70-1x proportions changed from 21.1% in 2016 to 50.6% in 2023, K56-1x from 15.8% to 37.0%, and K56-2x from 63.2% to 12.3%. Median real-world progression-free survival was 13.0 months [95% confidence interval (CI) 11.2-20.7] for K56-1x, 13.2 months (95% CI 9.0-28.1 months) for K56-2x, and 10.9 months (95% CI 9.9-15.3 months) for K70-1x; these differences were not statistically significant (log-rank p = 0.46). The prevalence of heart failure was comparable (<5% in all cohorts). In summary, our findings do not support improved outcomes with twice-weekly carfilzomib in RRMM. K56-1x may provide the best balance of efficacy, safety, and avoidance of time toxicity from frequent infusions.
The Moderating Role of Genetics on the Effectiveness of the Mindfulness-Based Stress Reduction for Breast Cancer (MBSR(BC)) Program on Cognitive Impairment
Park, Jong Y. , Rodriguez, Carmen S., Meng, Hongdao , Morgan, Sandra P. , Joshi, Anisha, Hueluer, Gizem, Wang, Julia R., Tinsley, Sara , Cox, Charles, Donovan, Kristine A. , Bornstein, Elizabeth, Lucas, Jean M., Fonseca, Tamela , Krothapalli, Mahathi, Padgett, Lynne, Nidamanur, Sreenidhi, Hornback, Estella, Patel, Diya , Chamkeri, Ramya, Reich, Richard R. , Morgan, Sandra , Tinsley, Sara , Park, Jong Y , Lengacher, Cecile A. , Kip, Kevin E. , Kiluk, John V. , Moscoso, Manolete S.

Mayo Clinic

Biological Research For Nursing | October 17, 2024 | Volume: 27 | Issue: 2 | Pages: 216-228

10.1177/10998004241289629 | PMID 39413359 Get It

Background Genetics may influence symptoms experienced by breast cancer survivors (BCS) by moderating the effects of stress-reducing interventions, including the Mindfulness-Based Stress Reduction (MBSR(BC)) program, to reduce symptom severity. As part of a larger clinical trial, the aim of this study was to evaluate genetic variants as moderators of MBSR(BC) on improvements among BCS in cognitive functioning and symptoms. Methods BCS ( n = 128) were randomized to MBSR(BC) or the Breast Cancer Education Support Program. Objective neuropsychological and subjective measures of cognitive performance, and psychological and physical symptoms were collected at baseline, 6, 12, and 26 weeks. Linear mixed models were implemented to identify MBSR(BC)’s effects over time. A total of 22 single nucleotide polymorphisms (SNPs) from 20 genes known to be related to these symptoms were investigated using genomic DNA. These SNPs were tested as moderators of MBSR(BC) program effects. Results Results showed MBSR(BC) participants experienced significantly greater benefits in cognitive functioning, however, the level of benefit varied based on one’s genetic profile. Effects sizes, consistency across similar measures were investigated. Among 22 candidate SNPs, rs4680 in COMT, rs1800497 in ANKK1, and rs6277 in DRD2 demonstrated the strongest, most consistent positive effects in moderating MBSR(BC)’s impact on cognitive outcomes. Conclusions Although the effects were small, this translational research may potentially identify BCS with genotypes that would be most influenced by the MBSR(BC) program. These results may be used to develop personalized intervention programs tailored to the genetic profile of each breast cancer survivor who received chemotherapy or chemotherapy and radiation. Trial Registration ClinicalTrials.gov, https://www.ClinicalTrials.gov Registration Number: NCT02786797.
Polygenic risk scores stratify breast cancer risk among women with benign breast disease
Sherman, Mark E. , Winham, Stacey J. , Vierkant, Robert A. , McCauley, Bryan M. , Scott, Christopher G. , Schrup, Sarah E. , Gaudet, Mia M. , Troester, Melissa A. , Pruthi, Sandhya , Bolla, Manjeet K. , Wang, Qin , Dennis, Joe, Chang‐Claude, Jenny , Obi, Nadia, Aronson, Kristan J. , García‐Closas, Montserrat , Yang, Xiaohong R. , Pharoah, Paul D.P., Easton, Douglas F., Vachon, Celine M, Schrup, Sarah, Radisky, Derek C. , Wang, Qin , Dennis, Joe , Michailidou, Kyriaki , Truong, Therese , Obi, Nadia , Aronson, Kristan J , García-Closas, Montserrat , Chanock, Stephen Jacob , Yang, Xiaohong R , Mavaddat, Nasim , Easton, Doug , Vachon, Celine M. , Winham, Stacey J , Vierkant, Robert A , Scott, Christopher , Gaudet, Mia M , Sherman, Mark E , Degnim, Amy C. , Couch, Fergus J. , Michailidou, Kyriaki , Guénel, Pascal , Truong, Thérèse , Murphy, Rachel A. , Ahearn, Thomas U. , Dunning, Alison M. , Easton, Douglas F.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 16, 2024 | Volume: 117 | Issue: 3 | Pages: 456-464

10.1093/jnci/djae255 | PMID 39412492 Get It

Abstract Background Most breast biopsies are diagnosed as benign breast disease, with 1.5- to 4-fold increased breast cancer risk. Apart from pathologic diagnoses of atypical hyperplasia, few factors aid in breast cancer risk assessment of these patients. We assessed whether a 313–single nucleotide variation (formerly single-nucleotide polymorphism) polygenic risk score stratifies risk of benign breast disease patients. Methods We pooled data from 5 Breast Cancer Association Consortium case-control studies (mean age = 59.9 years), including 6706 participants with breast cancer and 8488 participants without breast cancer. Using logistic regression, we estimated breast cancer risk associations by self-reported benign breast disease history and strata of polygenic risk score, with median polygenic risk score category among women without benign breast disease as the referent. We assessed interactions and mediation of benign breast disease and polygenic risk score with breast cancer risk. Results Benign breast disease history was associated with increased breast cancer risk (odds ratio [OR] = 1.48, 95% confidence interval [CI] = 1.37 to 1.60; P &lt; .001). Polygenic risk score increased breast cancer risk, irrespective of benign breast disease history (Pinteraction = .48), with minimal evidence of mediation of either factor by the other. Women with benign breast disease and polygenic risk score in the highest tertile had more than twofold increased odds of breast cancer (OR = 2.73, 95% CI = 2.41 to 3.09), and those with benign breast disease and polygenic risk score in the lowest tertile experienced reduced breast cancer risk (OR = 0.79, 95% CI = 0.70 to 0.91) compared with the referent group. Women with benign breast disease and polygenic risk score in the highest decile had a 3.7-fold increase (95% CI = 3.00 to 4.61) compared with those with median polygenic risk score without benign breast disease. Conclusion Breast cancer risks are elevated among women with benign breast disease and increase progressively with polygenic risk score, suggesting that optimal combinations of these factors may improve risk stratification.
Identification and quantitation of monoclonal proteins in polyclonal hypergammaglobulinemia background: a retrospective study
Martinez, Mark, Coker, Jon, Murray, David , Wang, Qian , Martinez, Mark, Dispenzieri, Angela , Willrich, Maria Alice V.

Mayo Clinic

American Journal of Clinical Pathology | October 15, 2024 | Volume: 162 | Issue: Supplement_1 | Pages: S155-S155

10.1093/ajcp/aqae129.344 Get It

Abstract Background Hypergammaglobulinemia poses a challenge for identifying and quantitating monoclonal proteins (M-protein). The Increased polyclonal immunoglobulin background can lead to imprecise estimation of the M-protein when quantitated by serum protein electrophoresis (SPEP). This is especially true using the perpendicular drop method of peak integration. Hypergammaglobulinemia also makes it difficult to detect small M-proteins on immunofixation electrophoresis. Overestimation of M-protein concentration can lead to unnecessary follow-ups while missing small M-proteins can mask the underlying diagnosis for patients. In this study, we retrospectively evaluated the prevalence and concentration of M-protein within polyclonal hypergamma backgrounds using immunocapture matrix-assisted laser desorption ionization time-of-flight mass-spectrometry (MASS-FIX). Methods We retrospectively analyzed 47061 unique patients tested for SPEP and MASS-FIX in 2022 at Mayo Clinic. If a patient underwent multiple tests during this period, only the first result was included in the analysis. Polyclonal hypergammaglobulinemia was defined as a gamma fraction &gt;1.7g/dL by SPEP. MASS-FIX was used to identify and isotype M-proteins. MASS-FIX was then combined with total immunoglobin quantitation (IgG, IgA or IgM) using nephelometry to quantify concentration of the M- protein using mathematical modeling (method currently under validation). Results Of the 47,061 unique patients, 24,796 were normal by SPEP (53%). M-spikes were present in 5,808 cases (12%). Hypogammaglobulinemia (gamma fraction &lt; 0.5g/dL) in 2897 cases (6%). Small non-quantifiable M-proteins by SPEP were present in 8363 cases (18%). [JC2] There were 4222 hypergamma cases in the cohort (9%), without a quantitative M-spike on SPEP. Of these, 16.1% (680/4222) patients had an M-protein by MASS-FIX. When polyclonal hypergamma was the sole SPEP abnormality, 5.5% were MASS-FIX positive. However, when a small abnormality pattern was observed within the polyclonal hypergamma background on SPEP, 50% of patients were MASS-FIX positive. The most common isotype was IgG (27.2%), followed by IgM (10.2%), IgA (8.1%), and biclonal (3.7%), which is similar to overall isotype distribution in other backgrounds. Using quantitative MASS-FIX, we identified that 95% MASS-FIX positive small monoclonal proteins in polyclonal hypergamma are &lt; 1 g/dL, which is the recommended limited of quantitation for M-protein using SPEP in setting of hypergammaglobulinemia. Conclusion Majority of polyclonal hypergammaglobulinemia cases (83.9%) do not have a monoclonal protein. MASS-FIX allows quantitation of small monoclonal proteins below the SPEP limit of quantitation, which can enhance our understanding of conditions which present with small M-proteins in a polyclonal hypergammaglobulinemia background. Small visual abnormalities within polyclonal hypergamma background on SPEP should be followed-up with immunofixation or MASS-FIX to confirm the presence or absence of M- proteins.
Incidence, Mechanisms, and Clinical Characteristics of Traumatic Iritis: A Population-Based Analysis
Wang, Kenny Y. , Kim, B. Michelle, Xu, Timothy T. , Hodge, David O. , Smith, Wendy M. , Reynolds, Margaret

Mayo Clinic

Ocular Immunology and Inflammation | October 15, 2024 | Volume: 33 | Issue: 3 | Pages: 378-384

10.1080/09273948.2024.2413899 | PMID 39405056 Get It